Stockscreener 앱 받기
50.26
1.68%
-0.86
시간 외 거래:
51.00
0.74
+1.47%
전일 마감가:
$51.12
열려 있는:
$51.57
하루 거래량:
2.14M
Relative Volume:
1.56
시가총액:
$5.93B
수익:
$3.22M
순이익/손실:
$-576.40M
주가수익비율:
-9.342
EPS:
-5.38
순현금흐름:
$-407.05M
1주 성능:
+8.88%
1개월 성능:
+9.69%
6개월 성능:
-11.17%
1년 성능:
-34.30%
1일 변동 폭
$48.88
$51.74
1주일 범위
$45.05
$51.74
52주 변동 폭
$40.53
$81.36
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
50.26 | 5.93B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics (CYTK) Projected to Post Earnings on Tuesday - MarketBeat
Allspring Global Investments Holdings LLC Has $4.11 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Van ECK Associates Corp - MarketBeat
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Cytokinetics' Latest Employee Compensation Strategy: $46.16 Stock Options and RSU Details Revealed - StockTitan
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Peregrine Capital Management LLC - MarketBeat
Cytokinetics EVP sells $91,960 in stock By Investing.com - Investing.com South Africa
Stifel maintains Buy on Cytokinetics stock, target at $80 By Investing.com - Investing.com Canada
Cytokinetics EVP sells $91,960 in stock - Investing.com
Cytokinetics (NASDAQ:CYTK) Stock Price Up 7.6%Time to Buy? - MarketBeat
Cytokinetics stock touches 52-week low at $41.69 amid market challenges - MSN
Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Cytokinetics jumps amid renewed takeover speculation - MSN
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year LowHere's What Happened - MarketBeat
Harvey Capital Management Inc. Acquires Shares of 22,105 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics upgraded by Morgan Stanley on upside potential - MSN
Morgan Stanley Upgrades Cytokinetics (CYTK) - MSN
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 - EIN News
Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70 - Marketscreener.com
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 - MSN
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 By Investing.com - Investing.com UK
Cytokinetics adds pharma veteran Landry to board ahead of drug launch - Investing.com Nigeria
Cytokinetics' (CYTK) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Citigroup - MarketBeat
Cytokinetics Names Robert E. Landry to Board of Directors - GlobeNewswire
Cytokinetics adds pharma veteran Landry to board ahead of drug launch By Investing.com - Investing.com South Africa
Cytokinetics Appoints Robert E. Landry to Board - TipRanks
Cytokinetics Names Robert E. Landry To Board Of Directors -February 11, 2025 at 07:53 am EST - Marketscreener.com
Cytokinetics Appoints Robert E. Landry to Board of Directors to Enhance Financial and Operational Expertise as Company Prepares for Commercialization - Nasdaq
abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month LowShould You Sell? - MarketBeat
JMP Securities maintains Cytokinetics stock with $78 target - MSN
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):